Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)’s share price gapped down before the market opened on Tuesday . The stock had previously closed at $3.67, but opened at $3.16. Lexicon Pharmaceuticals shares last traded at $3.37, with a volume of 650,789 shares.

Several research analysts recently weighed in on the company. BidaskClub cut Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, November 27th. Gabelli upgraded Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a research report on Wednesday, September 11th. Zacks Investment Research cut shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, November 16th. ValuEngine raised shares of Lexicon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 2nd. Finally, Citigroup cut shares of Lexicon Pharmaceuticals from a “buy” rating to a “neutral” rating and boosted their target price for the company from $3.00 to $4.00 in a research note on Friday, November 8th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $6.45.

The company has a current ratio of 8.11, a quick ratio of 8.01 and a debt-to-equity ratio of 1.42. The stock has a market capitalization of $375.14 million, a price-to-earnings ratio of -2.95 and a beta of 1.00. The stock has a 50-day moving average price of $3.62 and a 200 day moving average price of $3.90.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $2.11 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.31 by $0.80. The firm had revenue of $294.45 million during the quarter, compared to analyst estimates of $12.00 million. Lexicon Pharmaceuticals had a return on equity of 2,372.40% and a net margin of 49.78%. Lexicon Pharmaceuticals’s revenue for the quarter was up 4124.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.26) EPS. Equities research analysts anticipate that Lexicon Pharmaceuticals, Inc. will post 0.93 earnings per share for the current year.

In related news, Director Christopher J. Sobecki acquired 25,000 shares of Lexicon Pharmaceuticals stock in a transaction on Monday, September 16th. The stock was bought at an average cost of $2.55 per share, for a total transaction of $63,750.00. Following the completion of the transaction, the director now owns 112,493 shares of the company’s stock, valued at approximately $286,857.15. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Christopher J. Sobecki acquired 99,249 shares of Lexicon Pharmaceuticals stock in a transaction on Friday, September 13th. The shares were bought at an average price of $2.41 per share, with a total value of $239,190.09. Following the completion of the transaction, the director now directly owns 13,645 shares of the company’s stock, valued at approximately $32,884.45. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 178,749 shares of company stock worth $474,560. 6.40% of the stock is owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. acquired a new position in Lexicon Pharmaceuticals in the 3rd quarter valued at $1,590,000. Vanguard Group Inc. raised its position in shares of Lexicon Pharmaceuticals by 8.1% in the second quarter. Vanguard Group Inc. now owns 4,240,111 shares of the biopharmaceutical company’s stock valued at $26,670,000 after buying an additional 319,382 shares during the last quarter. Wedbush Securities Inc. lifted its stake in shares of Lexicon Pharmaceuticals by 105.1% in the third quarter. Wedbush Securities Inc. now owns 398,684 shares of the biopharmaceutical company’s stock worth $1,200,000 after buying an additional 204,345 shares in the last quarter. First Manhattan Co. lifted its stake in shares of Lexicon Pharmaceuticals by 7.3% in the second quarter. First Manhattan Co. now owns 2,949,979 shares of the biopharmaceutical company’s stock worth $18,555,000 after buying an additional 201,393 shares in the last quarter. Finally, Virtus ETF Advisers LLC purchased a new position in shares of Lexicon Pharmaceuticals in the second quarter worth about $901,000. 96.27% of the stock is owned by institutional investors and hedge funds.

Lexicon Pharmaceuticals Company Profile (NASDAQ:LXRX)

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Read More: Trading on Margin

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.